Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis

Abstract Background Subcutaneous immunotherapy (SCIT) is a well-validated and effective disease modification treatment for house dust mites (HDM)-induced allergic rhinitis (AR). Long-term post-treatment comparisons in children and adults treated with SCIT have rarely been published. This study aimed...

Full description

Bibliographic Details
Main Authors: Lei Ren, Chengshuo Wang, Lin Xi, Yunbo Gao, Yuan Zhang, Luo Zhang
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Online Access:https://doi.org/10.1186/s13223-023-00781-8
_version_ 1827983822293041152
author Lei Ren
Chengshuo Wang
Lin Xi
Yunbo Gao
Yuan Zhang
Luo Zhang
author_facet Lei Ren
Chengshuo Wang
Lin Xi
Yunbo Gao
Yuan Zhang
Luo Zhang
author_sort Lei Ren
collection DOAJ
description Abstract Background Subcutaneous immunotherapy (SCIT) is a well-validated and effective disease modification treatment for house dust mites (HDM)-induced allergic rhinitis (AR). Long-term post-treatment comparisons in children and adults treated with SCIT have rarely been published. This study aimed to evaluate the long-term efficacy of HDM-SCIT administered under a cluster schedule in children compared to adults. Methods This was an open-design, observational, long-term clinical follow-up study on children and adults with perennial AR treated with HDM-SCIT. The follow-up consisted of a three-year treatment duration plus a post-treatment follow-up of over three years. Results Patients in the pediatric (n = 58) and adult (n = 103) groups completed a post-SCIT follow-up of over three years. The total nasal symptom score (TNSS), combined symptom medication score (CSMS), and rhinoconjunctivitis quality-of-life questionnaire (RQLQ) score decreased significantly at T1 (three-year SCIT completed) and T2 (follow-up completed) in the pediatric and adult groups. In both groups, the improvement rate of TNSS (T0-T1) was moderately correlated with the baseline TNSS (r = 0.681, p < 0.001 and r = 0.477, p < 0.001 for children and adults, respectively). Only in the pediatric group, TNSS was significantly lower at T2 compared with that right after SCIT cessation (T1) (p = 0.030). Conclusions Children and adults with HDM-induced perennial AR could achieve a sustainable post-treatment efficacy for over three years (up to 13 years) following a three-year SCIT. Patients with relatively severe nasal symptoms at baseline may benefit more from SCIT. Children who have completed an adequate course of SCIT may gain further improvement in nasal symptoms after SCIT cessation.
first_indexed 2024-04-09T22:52:18Z
format Article
id doaj.art-eda4a3f9b12d41b09208b0a6db4d04c4
institution Directory Open Access Journal
issn 1710-1492
language English
last_indexed 2024-04-09T22:52:18Z
publishDate 2023-03-01
publisher BMC
record_format Article
series Allergy, Asthma & Clinical Immunology
spelling doaj.art-eda4a3f9b12d41b09208b0a6db4d04c42023-03-22T11:36:07ZengBMCAllergy, Asthma & Clinical Immunology1710-14922023-03-011911910.1186/s13223-023-00781-8Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitisLei Ren0Chengshuo Wang1Lin Xi2Yunbo Gao3Yuan Zhang4Luo Zhang5Department of Allergy, Beijing TongRen Hospital, Capital Medical UniversityDepartment of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical UniversityDepartment of Allergy, Beijing TongRen Hospital, Capital Medical UniversityDepartment of Allergy, Beijing TongRen Hospital, Capital Medical UniversityDepartment of Allergy, Beijing TongRen Hospital, Capital Medical UniversityDepartment of Allergy, Beijing TongRen Hospital, Capital Medical UniversityAbstract Background Subcutaneous immunotherapy (SCIT) is a well-validated and effective disease modification treatment for house dust mites (HDM)-induced allergic rhinitis (AR). Long-term post-treatment comparisons in children and adults treated with SCIT have rarely been published. This study aimed to evaluate the long-term efficacy of HDM-SCIT administered under a cluster schedule in children compared to adults. Methods This was an open-design, observational, long-term clinical follow-up study on children and adults with perennial AR treated with HDM-SCIT. The follow-up consisted of a three-year treatment duration plus a post-treatment follow-up of over three years. Results Patients in the pediatric (n = 58) and adult (n = 103) groups completed a post-SCIT follow-up of over three years. The total nasal symptom score (TNSS), combined symptom medication score (CSMS), and rhinoconjunctivitis quality-of-life questionnaire (RQLQ) score decreased significantly at T1 (three-year SCIT completed) and T2 (follow-up completed) in the pediatric and adult groups. In both groups, the improvement rate of TNSS (T0-T1) was moderately correlated with the baseline TNSS (r = 0.681, p < 0.001 and r = 0.477, p < 0.001 for children and adults, respectively). Only in the pediatric group, TNSS was significantly lower at T2 compared with that right after SCIT cessation (T1) (p = 0.030). Conclusions Children and adults with HDM-induced perennial AR could achieve a sustainable post-treatment efficacy for over three years (up to 13 years) following a three-year SCIT. Patients with relatively severe nasal symptoms at baseline may benefit more from SCIT. Children who have completed an adequate course of SCIT may gain further improvement in nasal symptoms after SCIT cessation.https://doi.org/10.1186/s13223-023-00781-8Allergic rhinitisEfficacyLong-termPediatricSubcutaneous immunotherapy
spellingShingle Lei Ren
Chengshuo Wang
Lin Xi
Yunbo Gao
Yuan Zhang
Luo Zhang
Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis
Allergy, Asthma & Clinical Immunology
Allergic rhinitis
Efficacy
Long-term
Pediatric
Subcutaneous immunotherapy
title Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis
title_full Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis
title_fullStr Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis
title_full_unstemmed Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis
title_short Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis
title_sort long term efficacy of hdm scit in pediatric and adult patients with allergic rhinitis
topic Allergic rhinitis
Efficacy
Long-term
Pediatric
Subcutaneous immunotherapy
url https://doi.org/10.1186/s13223-023-00781-8
work_keys_str_mv AT leiren longtermefficacyofhdmscitinpediatricandadultpatientswithallergicrhinitis
AT chengshuowang longtermefficacyofhdmscitinpediatricandadultpatientswithallergicrhinitis
AT linxi longtermefficacyofhdmscitinpediatricandadultpatientswithallergicrhinitis
AT yunbogao longtermefficacyofhdmscitinpediatricandadultpatientswithallergicrhinitis
AT yuanzhang longtermefficacyofhdmscitinpediatricandadultpatientswithallergicrhinitis
AT luozhang longtermefficacyofhdmscitinpediatricandadultpatientswithallergicrhinitis